Literature DB >> 17532502

Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury.

Ozkan Ates1, Suleyman R Cayli, Ilal Gurses, Yusuf Turkoz, Ozcan Tarim, Celal O Cakir, Ayhan Kocak.   

Abstract

Spinal cord injury (SCI) results in loss of function below the lesion. Secondary injury following the primary impact includes a number of biochemical and cellular alterations leading to tissue necrosis and cell death. Influx of Na(+) ions into cells has been postulated to be a key early event in the pathogenesis of secondary traumatic and ischemic central nervous system injury. Previous studies have shown that some voltage-sensitive sodium channel blockers provide powerful neuroprotection. The purpose of the present study was to compare the neuroprotective effect of three sodium channel blockers-mexiletine, phenytoin and riluzole--after SCI. Ninety rats were randomly and blindly divided into five groups of 18 rats each: sham-operated group, trauma group (bolus injection of 1 mL physiological saline intraperiteonally [i.p.]), mexiletine treatment group (80 mg/kg, i.p.), phenytoin treatment group (200 mg/kg, i.p.) and riluzole treatment group (8 mg/kg, i.p.). Twenty-four hours after injury, the rats were killed for determination of spinal cord water content and malondialdehyde (MDA) levels. Motor function scores of six rats from each group were evaluated weekly for six weeks. Then the rats were killed for histopathological assessment. Although all the treatment groups revealed significantly lower MDA levels and spinal cord edema than the trauma group (p<0.05), the riluzole and mexiletine treatment groups were better than the phenytoin treatment group. In the chronic stage, riluzole and mexiletine treatment achieved better results for neurobehavioral and histopathological recovery than phenytoin treatment. In conclusion, all the tested Na(+) blockers had a neuroprotective effect after SCI; riluzole and mexiletine were superior to phenytoin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17532502     DOI: 10.1016/j.jocn.2006.03.023

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  33 in total

Review 1.  Spinal cord injury: a systematic review of current treatment options.

Authors:  David W Cadotte; Michael G Fehlings
Journal:  Clin Orthop Relat Res       Date:  2011-03       Impact factor: 4.176

2.  Pathology dynamics predict spinal cord injury therapeutic success.

Authors:  Cassie S Mitchell; Robert H Lee
Journal:  J Neurotrauma       Date:  2008-12       Impact factor: 5.269

Review 3.  Sodium channels in astroglia and microglia.

Authors:  Laura W Pappalardo; Joel A Black; Stephen G Waxman
Journal:  Glia       Date:  2016-02-26       Impact factor: 7.452

Review 4.  Ion channels as drug targets in central nervous system disorders.

Authors:  A M Waszkielewicz; A Gunia; N Szkaradek; K Słoczyńska; S Krupińska; H Marona
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  The Effect of Non-Gabapentinoid Anticonvulsants on Sensorimotor Recovery After Human Spinal Cord Injury.

Authors:  Freda M Warner; Catherine R Jutzeler; Jacquelyn J Cragg; Bobo Tong; Lukas Grassner; Frank Bradke; Fred Geisler; John K Kramer
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

6.  Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current.

Authors:  S Weiss; D Benoist; E White; W Teng; D A Saint
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 7.  A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury.

Authors:  Brian K Kwon; Elena Okon; Jessica Hillyer; Cody Mann; Darryl Baptiste; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-04-14       Impact factor: 5.269

8.  Voltage-gated sodium channel Nav 1.5 contributes to astrogliosis in an in vitro model of glial injury via reverse Na+ /Ca2+ exchange.

Authors:  Laura W Pappalardo; Omar A Samad; Joel A Black; Stephen G Waxman
Journal:  Glia       Date:  2014-04-17       Impact factor: 7.452

9.  Does dexmedetomidine reduce secondary damage after spinal cord injury? An experimental study.

Authors:  Adem Aslan; Mustafa Cemek; Olcay Eser; Korhan Altunbaş; Mehmet Emin Buyukokuroglu; Murat Cosar; Orhan Baş; Yuksel Ela; Huseyin Fidan
Journal:  Eur Spine J       Date:  2009-01-08       Impact factor: 3.134

Review 10.  Spinal cord injury: time to move?

Authors:  Serge Rossignol; Martin Schwab; Michal Schwartz; Michael G Fehlings
Journal:  J Neurosci       Date:  2007-10-31       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.